文献速递脑血管病

大核心梗死卒中患者抗凝使用与血管内取栓:SELECT2试验二次分析

Anticoagulation Use and Endovascular Thrombectomy in Patients with Large Core Stroke: A Secondary Analysis of the SELECT2 Trial.
PubMed 文献 · Ann Neurol · 2024-07-22

SELECT2试验二次分析显示,基线使用口服抗凝药(OAC)的大核心梗死患者中,血管内取栓(EVT)组与药物治疗组临床结局无显著差异(调整广义优势比0.89),而无OAC患者中EVT结局显著更优(调整广义优势比1.87,p=0.02)。OAC组合并症更多,但调整后结果一致,且未观察到实质血肿或症状性颅内出血。

要点

  • 大核心梗死合并OAC使用患者中,EVT与药物治疗临床结局无显著差异。
  • 无OAC患者中EVT结局显著优于药物治疗(调整广义优势比1.87)。
  • OAC不应单独作为排除EVT的理由,需结合合并症和缺血损伤范围个体化决策。

核心结论

  • 在大核心梗死患者中,基线OAC使用与EVT后临床结局无显著改善相关,但OAC使用本身不应排除患者接受EVT,需结合基线合并症和缺血损伤范围进行个体化治疗决策。

研究设计与样本

  • SELECT2试验(NCT03876457)的二次分析,纳入EVT组180例和药物治疗组172例大核心梗死患者,比较基线OAC使用与否的结局。

主要发现

  • EVT组29/180例(16%)和药物治疗组18/172例(10%)报告基线OAC使用。
  • OAC组中EVT与药物治疗临床结局无显著差异(EVT 6[4-6] vs 药物治疗5[4-6],调整广义优势比0.89[0.53-1.50])。
  • 无OAC组中EVT结局显著优于药物治疗(EVT 4[3-6] vs 药物治疗5[4-6],调整广义优势比1.87[1.45-2.40],p=0.02)。
  • OAC组合并症更多:心房颤动70% vs 17%,充血性心力衰竭28% vs 10%,高血压87% vs 72%。
  • OAC组接受EVT者任何出血率更高(86% vs 无OAC 70%),但EVT和药物治疗组中OAC使用均未观察到实质血肿或症状性颅内出血。

临床怎么用

  • 作者认为,OAC使用本身不应排除患者接受EVT,但需考虑基线合并症和缺血损伤范围进行个体化治疗决策。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Endovascular thrombectomy (EVT) safety and efficacy in patients with large core infarcts receiving oral anticoagulants (OAC) are unknown. In the SELECT2 trial (NCT03876457), 29 of 180 (16%; vitamin K antagonists 15, direct OACs 14) EVT, and 18 of 172 (10%; vitamin K antagonists 3, direct OACs 15) medical management (MM) patients reported OAC use at baseline. EVT was not associated with better clinical outcomes in the OAC group (EVT 6 [4-6] vs MM 5 [4-6], adjusted generalized odds ratio 0.89 [0.53-1.50]), but demonstrated significantly better outcomes in patients without OAC (EVT 4 [3-6] vs MM 5 [4-6], adjusted generalized odds ratio 1.87 [1.45-2.40], p = 0.02). The OAC group had higher comorbidities, including atrial fibrillation (70% vs 17%), congestive heart failure (28% vs 10%), and hypertension (87% vs 72%), suggesting increased frailty. However, the results were consistent after adjustment for these comorbidities, and was similar regardless of the type of OACs used. Whereas any hemorrhage rates were higher in the OAC group receiving EVT (86% in OAC vs 70% in no OAC), no parenchymal hemorrhage or symptomatic intracranial hemorrhage were observed with OAC use in both the EVT and MM arms. Although we did not find evidence that the effect was due to excess hemorrhage or confounded by underlying cardiac disease or older age, OAC use alone should not exclude patients from receiving EVT. Baseline comorbidities and ischemic injury extent should be considered while making individualized treatment decisions. ANN NEUROL 2024;96:887-894.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Pujara DK, Hussain MS, Abraham MG, et al. Anticoagulation Use and Endovascular Thrombectomy in Patients with Large Core Stroke: A Secondary Analysis of the SELECT2 Trial. Ann Neurol. 2024. PMID: 39039739. doi:10.1002/ana.27021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。